Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide to Prevent Chronic Lung Disease in Pre-term Infants
2004-002312-29Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Oct 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nitric oxide in chronic lung disease and respiratory distress syndrome (RDS), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Primary Efficacy Variable. Started Oct 2004; status: completed.
02
Drugs
nitric oxide
03
Conditions
chronic lung diseaserespiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2004-002312-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002312-29.